Biol Reprod
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


BOR - Papers in Press, published online ahead of print December 27, 2002.
Biol Reprod 2002, 10.1095/biolreprod.102.007963
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
68/6/1959    most recent
biolreprod.102.007963v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gopalkrishnan, K.
Right arrow Articles by Puri, C.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gopalkrishnan, K.
Right arrow Articles by Puri, C.P.
Agricola
Right arrow Articles by Gopalkrishnan, K.
Right arrow Articles by Puri, C.P.
BIOLOGY OF REPRODUCTION 68, 1959–1967 (2003)
DOI: 10.1095/biolreprod.102.007963
© 2003 by the Society for the Study of Reproduction, Inc.


Mechanisms of Hormone Action

Effects of an Antiprogestin Onapristone on the Endometrium of Bonnet Monkeys: Morphometric and Ultrastructural Studies

Kamala Gopalkrishnan, R.R. Katkam, Geetanjali Sachdeva, S.D. Kholkute, Varsha Padwal, and C.P. Puri1

National Institute for Research in Reproductive Health, Indian Council of Medical Research, Parel, Mumbai 400012, India


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Our previous studies demonstrated the ability of low doses of antiprogestin ZK 98.299 (onapristone) to inhibit fertility in bonnet monkeys. In the present study cumulative effects of low doses of ZK 98.299 on the endometrial cytoarchitecture of bonnet monkeys were analyzed. Treatment with either the vehicle (n = 3) or onapristone at 2.5 mg (n = 4) or 5.0 mg (n = 3) was initiated on Day 5 of the first menstrual cycle and thereafter repeated every third day for four to seven consecutive cycles. The last treatment cycles were anovulatory in two animals treated with 2.5 mg and all animals treated with 5.0 mg. Endometrial biopsies were collected on Day 8 after the midcycle estradiol peak in ovulatory menstrual cycles and on Day 20 in anovulatory menstrual cycles during the last treatment cycle. Ultrathin sections of the fixed endometrium were stained with toluidine blue for morphometric analysis and uranyl acetate and lead citrate for ultrastructural analysis. The ZK 98.299-treated animals showed a dose-dependent endometrial atrophy as evident by a decrease in the height and diameter of the glands and early signs of compaction in the stroma. Ultrastructural analysis also revealed dose-dependent degenerative changes in the subcellular organelles such as the nucleus, mitochondria, endoplasmic reticulum, lysosomes, and Golgi apparatus. This suggests that long-term treatment with low doses of ZK 98.299 leads to the suppression of estrogen-dependent endometrial proliferation. However, this blockade operates independent of estradiol receptor (ER) and progesterone receptor (PR) concentrations as the expressions of these steroid receptors did not show any significant changes even after prolonged treatment. The study demonstrated an antiestrogenic effect of ZK 98.299 on endometrium after prolonged treatment in bonnet monkeys.

bonnet monkeys, antiprogestin, endometrium, morphology, ultrastructure, ZK 98.299 (onapristone)


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The ovarian steroids, progesterone and estradiol, drive either proliferation or differentiation, depending on their site of action. For example, estradiol induces proliferation in the endometrial functionalis and oviduct, and differentiation in the ciliated and secretory epithelium of the oviduct, whereas progesterone induces differentiation in the endometrial functionalis and mitogenic effects on the endometrial basalis, stroma, and spiral arteries [1]. Thus these hormones act in concert to regulate the growth and development of endometrium. This is in contrast to their roles in the oviduct, where estradiol exerts its function in an unopposed manner irrespective of the presence of progesterone [1, 2].

Over the years, several structurally similar synthetic ligands, RU 486, ZK 98.734, and ZK 98.299 have been developed to block progesterone function during the pre- and peri-implantation periods and hence may help regulate fertility [3, 4]. It also has been proposed that the antiprogestins may be useful in the treatment of endometriosis, meningiomas, leiomyomatas [5, 6], and breast cancer [5]. However, the risks of an increased unopposed estrogen action leading to malignancy and other long-term effects as the result of prolonged use of these antiprogestins need to be evaluated in a suitable animal model prior to their therapeutic use.

The antiprogestin onapristone (ZK 98.299) is a 11ß-aryl substituted steroidal progesterone antagonist with high affinity to progesterone receptors (PR) and glucocorticoid receptors [7, 8]. Daily administration of high doses of this antiprogestin (25 mg) blocked the anticipated rise in the midcycle bioactive luteinizing hormone surge, serum estradiol levels, and ovulation [9]. In women, long-term administration of high doses of RU 486 led to the disruption of ovarian function, resulting in amenorrhea [10]. On the other hand, weekly administration of onapristone at lower doses (5.0 or 10.0 mg) had no effect on gonadal hormonal concentrations, ovulation, and menstrual cycle length. However, endometrial development was still found to be impaired in treated bonnet monkeys [11]. Similar observations were recorded in women administered with a daily dose of 1.0 mg RU 486 for 5 mo [12]. This led to the conclusion that the endometrium is more sensitive to antiprogestin action than other target tissues such as the hypothalamus, pituitary, and ovary. However, it still remains to be ascertained whether long-term antiprogestin treatment at low dosages causes endometrial hyperplasia because of an unopposed estrogenic action.

The present study evaluated long-term effects of low-dose onapristone treatment on endometrial development at the subcellular level and set out to determine whether the long-term treatment would induce any hyperplastic changes in the endometrium.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Animals

Female bonnet monkeys (Macaca radiata) weighing between 3.5 and 4.5 kg and showing at least 2 consecutive normal ovulatory menstrual cycles were selected for the study. The monkeys were individually caged under controlled photoperiod and temperature [13]. The study was carried out between the months of September and April. The menstrual cycle length and the duration of menses of each animal was recorded by daily vaginal swab examination. The study was approved by the Institutional Ethics Committee on the Use and Care of Animals in Biomedical Research.

Estimation of Hormonal Levels

Estradiol and progesterone levels were estimated in serum samples by specific radioimmunoassays as described previously [13]. The inter- and intra-assay coefficients of variation were 8% and 7%, respectively, for estradiol and 11% and 13%, respectively, for progesterone. The reagents were provided by the World Health Organization under the Programme for the Provision of Matched Assay Reagents for the Radioimmunoassay of Hormones in Reproductive Physiology [14].

Treatment with Onapristone

Ten adult female bonnet monkeys were randomly divided into three groups. Animals in group 1 (n = 3) were administered subcutaneously (on hind limbs) with vehicle (benzyl benzoate: castor oil, 9:1), and animals in groups 2 (n = 4) and 3 (n = 3) were similarly treated with 2.5 and 5.0 mg onapristone, respectively. Treatment was initiated on Day 5 of the first menstrual cycle, and thereafter it was administered every third day for four to seven consecutive cycles.

Endometrial Biopsies

Endometrial biopsies were collected from control- and onapristone-treated animals during the final treatment cycles. In animals with ovulatory cycles, the biopsy was collected on Day 8 after the midcycle estradiol peak, whereas in animals with anovulatory cycles, biopsy was taken on Day 20 of the cycle.

Tissue Preparation

Part of the endometrial tissue was fixed immediately in modified Karnovsky fluid [15] prepared in cacodylate buffer for ultrastructural analysis, and the other portion was fixed in Bouin fluid for immunohistochemical analysis. The tissue postfixed in 1% osmium tetroxide for ultrastructural analysis was dehydrated in ascending grades of acetone and embedded in araldite. Semithin (0.5 µ) sections were cut and stained with toluidine blue for morphometric analysis.

Morphologic Features of the Glands

The gland cell height and diameter were measured using an ocular micrometer. Only those gland cells where the cells extended from the basement membrane to cilia in the section were counted. Similarly, the gland diameters were recorded only when the epithelial cells were in the plane from the basement membrane to the ciliated luminal surface. This systematic sampling method was adopted to avoid overestimation arising by the way of a longitudinal or tangential cut through the tubular structures. For each sample, a minimum of 20 fields were examined from different blocks in four to six sections. The number of glands seen under x400 magnification was counted in at least 20 fields, four from each of the four to six blocks, and means were calculated. To calculate the gland mitosis, at least 1000 cells were examined under oil immersion, and only definite mitotic figures with the absence of the nuclear membrane were included in the count. The amount of pseudostratification and secretion in the glandular lumen was also recorded on a scale of 0–3 (0 = absent, 1 = mild, 2 = moderate, 3 = marked).

In the stroma, morphological features recorded were predecidual reaction, amount of leukocytic infiltration, amount of extravasation, and stromal edema (same scoring as used for glands).

Electron Microscopy

The ultrathin sections of endometrial tissue showing interference colors ranging from gold to grey were mounted on uncoated copper grids (200 mesh) and stained with uranyl acetate and lead citrate [16]. These sections were observed under a Philips 400T transmission electron microscope (Philips, Eindhoven, the Netherlands) at 80 kV.

A modified scoring system was adapted to record ultrastructural features of endometrium [17]. The modifications were made mainly for the presence of the nucleolar channel system and the largest mitochondrial diameter. The mean score was calculated for the control and two treatment groups. To calculate the mean score, the number of observations for each score was multiplied by the score and the sum total was divided by the number of observations made.

Immunohistochemical Localization of Endometrial Estrogen Receptor and Progesterone Receptor

In brief, the sections were deparaffinized in xylene and rehydrated through various grades of alcohol in distilled water. Immunoperoxidase staining to localize the estrogen receptor (ER) and PR was performed using Vectastain ABC kits (Burlingame, CA) on sections of endometria from control and treated animals. Sections were blocked with 1% BSA in PBS (120 mM NaCl, 2.7 mM KCl, and 10 mM phosphate buffer, pH 7.4) followed by incubation with the primary antibody for PR (MA1-410; Affinity Bioreagents, Golden, CO) at 1:50 dilution or ER (MA1-310, Affinity Bioreagents) at 1:100 dilution for 1 h at room temperature. After washing with PBS, the sections were incubated with biotinylated goat antimouse secondary antibody (DAKO, Glostrup, Denmark) at 1:100 dilution for 30 min. After a PBS rinse, the endogenous peroxidase was inactivated by a 30-min incubation with 0.3% H2O2 in methanol. This was followed by rehydration in PBS for 30 min. Sections were then incubated with avidin:biotinylated horse radish peroxidase macromolecular complex (ABC) for 30 min followed by an addition of diaminobenzidine in PBS for 5 min to complete the reaction. The sections were dehydrated, cleared in xylene, mounted, and viewed under the microscope.

The resulting staining for ER and PR was evaluated on a Zeiss microscope (Carl Zeiss, Oberkochen, Germany) at low (x10) and high (x40) magnifications. Intensity of the staining was judged as absent (-), weak (+), moderate (++), and strong (+++). Photomicrographs were taken using Kodak Gold-MAX 100 ASA film (Eastman Kodak, Rochester, NY) at x120 magnification.

Intensity of immunohistochemical staining for ER and PR in both endometrial glands and stroma for each animal in the control and treatment groups was evaluated by two independent observers using the semiquantitative HSCORE = Pi(i + 1) method, where i is the intensity of staining (a value of 1, 2, or 3, corresponding to weak, moderate, or strong staining, respectively) and Pi is the percentage of staining cells for each intensity (varying from 0% to 100%) [18]. At least 1000 cells were counted, which corresponded to four to six sections per slide.

Statistical Analyses

Unpaired Student t-test was applied to determine differences in hormonal concentrations. One-way ANOVA with Duncan multiple range test was applied to determine group differences in morphometric parameters. Analysis of semiquantitative HSCORE for significance was carried out using Mann-Whitney rank sum test. The data were considered to be significant when P <= 0.05.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Hormonal Levels

All animals in the control group displayed follicular and luteal phases of normal length with optimal serum concentrations of estradiol and progesterone. Serum concentrations of estradiol and progesterone during the pretreatment and four treatment cycles in a representative animal (#266) from the 2.5-mg treatment group are shown in Figure 1. All cycles were ovulatory in two animals treated with 2.5 mg onapristone for four cycles. Serum concentrations of estradiol and progesterone on the day of biopsy were 50 pg/ml and 3.28 ng/ml, respectively, in these animals. However, animals that were treated with 2.5 mg for 6 cycles became anovulatory. Thus the duration of the treatment did adversely affect the serum concentrations of gonadal hormones.



View larger version (28K):
[in this window]
[in a new window]
 
FIG. 1. Circulatory levels of estradiol (open circles) and progesterone (closed circles) during pretreatment and four treatment cycles in a representative animal (#266, ovulatory) of the 2.5-mg treatment group

All animals treated with 5.0 mg onapristone also showed anovulation as evident by low serum concentrations of estradiol and progesterone (Fig. 2). However, the anovulatory cycles were of normal duration in these animals. Serum concentrations of estradiol increased gradually during the midfollicular phase, which was followed by a sharp decline. The profile appeared to be similar to that seen in normal cycles. However, serum concentrations of progesterone did not increase above 1 ng/ml (Table 1).



View larger version (25K):
[in this window]
[in a new window]
 
FIG. 2. Circulatory levels of estradiol (open circles) and progesterone (closed circles) during pretreatment and fourth treatment cycles in representative animals of 2.5-mg (#104, anovulatory) and 5.0-mg (#162, anovulatory) treatment groups


View this table:
[in this window]
[in a new window]
 
TABLE 1. Serum estradiol and progesterone concentrations and ovulation status after onapristone treatment.*

Morphological Analysis

Endometria from the control animals in the midluteal phase showed well-developed glands with secretory activity, stromal edema (Fig. 3A), and formation of spiral arteries, whereas in the 2.5-mg treatment group endometrial glands showed increased mitotic activity, epithelial pseudostratification, and reduced diameter compared with the control group. Stroma exhibited the early signs of compaction (Fig. 3B). In the higher dose group (5.0 mg), diameter of the glands was further decreased. The stroma showed no signs of vascular and stromal differentiation (Fig. 3C).



View larger version (92K):
[in this window]
[in a new window]
 
FIG. 3. Histomorphological analysis of representative endometrial tissues from bonnet monkeys treated with vehicle (a) and 2.5 mg (b) and 5.0 mg (c) onapristone. Mitoses (arrow) leading to pseudostratification were observed in endometrial glands in 2.5-mg-treated animals (b). No mitoses were observed within shrinking glands in endometria from 5.0-mg-treated animals. However, secretory material (arrows) was seen in glandular cells (c; original magnification x1250)

The results of the morphometric evaluation of glandular and stromal features of endometria in control and treatment groups are presented in Tables 2 and 3, respectively. Endometria from the 2.5-mg-treated ovulatory animals showed weak signs of secretion in the glandular cells. Mitotic activity in endometrial glandular cells was also evident in these animals (#186, #266). However, in the animals that became anovulatory (#104, #244) following 2.5 mg onapristone treatment, endometrial glands were inactive and apparently devoid of secretory activity.


View this table:
[in this window]
[in a new window]
 
TABLE 2. Morphometric measurements of endometrial glandular features in control and onapristone-treated animals.{dagger}


View this table:
[in this window]
[in a new window]
 
TABLE 3. Morphometric measurements of endometrial stromal features in control and onapristone-treated animals.*

Endometria from the animals in the 5.0-mg treatment group showed a further decrease in the height and diameter of the glands resulting in an increased number of glands per high power field (P < 0.05; Table 2). The glands did not show any secretory activity. Pseudostratification of glandular cells was seen with the absence of subnuclear vacuoles.

Stromal features such as predecidual reaction, edema, and mitosis scored much lower in treatment groups as compared with the control group (Table 3). The mitotic index remained unaffected in endometrial stroma in 2.5-mg-treated ovulatory animals. An increased number of mast cells were seen in the endometrial stromal tissue from the 2.5-mg treatment group as compared with controls. Blood vessels were significantly dilated in the compact spindly stroma in the 5.0-mg treatment group as compared with vehicle-treated animals.

Ultrastructural Analysis

The electron microscopic analysis of endometrial glandular and stromal cells in vehicle-treated animals revealed characteristic features of a developed secretory endometrium (Fig. 4, A–D; Fig. 5A). The gland cell nuclei demonstrated an euchromatin pattern with only little chromatin condensation. Nucleoli were well developed. The nuclear envelope and endoplasmic reticulum system were extensively developed to produce a labyrinthine complex throughout the cytoplasm. The glandular cytoplasm also showed some secretory material such as glycoprotein and free glycogen particles (Fig. 4, A and B). A well-developed Golgi system with a number of dilated vacuoles and vesicles were observed (Fig. 4, A and B). A ribosomal endoplasmic reticulum (RER) system, represented by short and dilated cisternae enclosing the electron lucent material, was most prominent in basal cytoplasm surrounded by numerous small and large mitochondria. The mitochondria exhibited a well-organized internal structure with transverse cristae, whereas few were irregularly developed with a loss of their cristae (Fig. 4, C and D). Numerous long microvilli were seen on the cell surface.



View larger version (113K):
[in this window]
[in a new window]
 
FIG. 4. Ultrastructural analysis of representative endometrial glandular cells from bonnet monkeys treated with vehicle (AD), 2.5 mg (EG), and 5.0 mg (H) onapristone. A) The apical glandular epithelial cells extending into the lumen showed glycogen (G). Microvilli (MV) underlying the luminal surface, secretory vesicles (SV), and granular endoplasmic reticulum (ER) were also seen (original magnification x1400). B) Basal glandular epithelial cells showed prominent nuclei (N), nucleoli (NC), ER, and intact basal lamina (BL). Plenty of mitochondria (M) were also observed (original magnification x1400). C) M, rough endoplasmic reticulum (RER), and lipid droplets (L) seen at higher magnification (magnification x11 000). D) Desmosomes ({Uparrow}) between two gland cells, giant M, and disorganized RER were observed in glandular cell cytoplasm (original magnification x8500). E) Degeneration and loss of most of the cellular organelles was observed in endometrial glandular cells. Apical end of gland cells showed fewer microvilli (original magnification x1400). F) N of the glandular cells with prominent NC and myelin bodies (MY) in the cytoplasm (original magnification x1400). G) The glandular cell cytoplasm with accumulation of L with interdigitation of plasma membrane of cells ({Uparrow}; original magnification x5200). H) Irregular indented nuclei with absence of nucleolus and fewer microvilli were observed (original magnification x1400)



View larger version (200K):
[in this window]
[in a new window]
 
FIG. 5. Ultrastructural analysis of representative endometrial stromal cells from bonnet monkeys treated with vehicle (A) and 2.5 mg (B and C) and 5.0 mg (D) onapristone. A) Well-developed endoplasmic reticular system; several vacuoles (V) with cross-sectioned collagen fiber were seen along with some small glycogen particles (GL) and extracellular matrix edema (original magnification x2400). B) Formation of myelin bodies (MY) and collagen fibers (C) was observed (original magnification x2400). C) Many V and degenerative appearances interspersed in the fibrous stroma were observed (original magnification x3000). D) Accumulation of lipids (L) and secretory material was seen in the intercellular space of stromal cells (S; original magnification x3000)

The stromal cells showed lipid droplets, predecidual changes with well-developed RER, and several phagocytic vesicles with cross-sectioned collagen fibers (Fig. 5A).

Endometria from 2.5-mg-treated animals (Fig. 4E) showed a general loss of cell organelles. A delay in maturation of the endometrium was indicated by proliferative changes and small round glands in two animals (#186, #246) that remained ovulatory even after onapristone treatment. Endometria of the two anovulatory animals (#104, #244) showed degenerative changes like vacuolation and formation of myelin bodies in glandular and stromal cells (Figs. 4F and 5B). The desmosomes were absent with characteristic infolding of the plasma membrane (Fig. 4G). The cytoplasmic organelles were fewer, and nuclei with prominent nucleoli were seen. Fibrous stroma was marked by the presence of vacuoles in the cytoplasm (Fig. 5C).

At a higher dose (5.0 mg), total degeneration with an increased appearance of lipofuchsin bodies, loss of other cellular organelles, and marked vacuolation was observed in endometrial glandular cells (Fig. 4H). An increase in the intracellular spaces and pseudostratification of the nuclei could also be seen. There was accumulation of secretions in the spaces between glandular cells. The nuclei were highly indented, giving rise to a segmented appearance, and were without nucleoli (Fig. 4H). There was very little lumen with few microvilli at the luminal surface. The stroma also showed accumulation of secretory material and lipids in the intercellular space in otherwise degenerative cells (Fig. 5D). The mean scores for ultrastructural analysis of endometrial cell organelles are given in Table 4.


View this table:
[in this window]
[in a new window]
 
TABLE 4. Endometrial ultrastructural scores in control and onapristone-treated bonnet monkeys.*

Endometrial ER and PR

No significant change was observed in the localization and expression of ER in the nuclei of endometrial glandular epithelial and stromal cells between control and treated animals (Fig. 6). Similarly, localization or expression of the endometrial PR protein in the glandular as well as in the stromal compartments remained unaltered in 2.5-mg-treated animals (Fig. 7b) as compared with the control animals (Fig. 7A). However, the expression of PR was significantly (P < 0.01) reduced in the endometrial glandular epithelial as well as stromal cells in 5.0-mg-treated animals (Fig. 7C) as compared with controls.



View larger version (114K):
[in this window]
[in a new window]
 
FIG. 6. Immunohistochemical localization of estrogen receptors (ER) in the endometria of bonnet monkeys treated with vehicle (a) and 2.5 mg (b) and 5.0 mg (c) onapristone. Immunostaining was detected mainly in the nuclei of glandular epithelial and stromal cells



View larger version (113K):
[in this window]
[in a new window]
 
FIG. 7. Immunohistochemical localization of progesterone receptors (PR) in the endometria of bonnet monkeys treated with vehicle (a) and 2.5 mg (b) and 5.0 mg (c) onapristone. Immunoreactive PR protein was localized in the nuclei of glandular epithelial and stromal cells


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The present study suggests that long-term treatment with onapristone (ZK 98.299) impairs endometrial development and causes endometrial atrophy. A delay in endometrial maturation as indicated by proliferative changes with characteristic mitotic figures and small round glands were observed in the endometria of treated animals. However, no hyperplastic changes were observed following low doses (2.5 and 5.0 mg) of onapristone treatment for four to seven consecutive cycles.

Morphometric analysis revealed a drastic reduction in the diameter and height of the endometrial glandular cells in treated animals, thereby indicating impaired glandular function following antiprogestin treatment. Two animals (#104, #232) that became anovulatory following a 2.5-mg onapristone treatment for six cycles showed myelin bodies and mast cells in the endometrial stroma. Myelin bodies could have originated because of the degeneration of cellular organelles, especially mitochondria, whereas an increase in the number of mast cells could have occurred because of fibrosis [19]. These mast cells were not seen in the endometria from control and treated ovulatory animals.

Animals (#186, #266) that remained ovulatory following a 2.5-mg onapristone treatment for four cycles showed a concomitant increase in the mitotic index, whereas endometria from the animals that became anovulatory following treatment with 2.5 or 5.0 mg of onapristone showed a negligible mitotic index in glandular and stromal cells. In these anovulatory animals, the serum progesterone concentrations were low and the estradiol levels were within the range usually encountered during the normal follicular phase [13]. This should have led to increased cell proliferation in the endometrial epithelial cells. However, we failed to note any increase in mitotic activity in the glandular epithelium of endometria obtained from the treated animals. In contrast, severely atrophied endometrium was observed in these animals.

Ultrastructural analysis of endometria from treated animals revealed the presence of large vacuoles, membranous inclusions, and myelin-like bodies. These features were suggestive of the disintegration of cytoplasmic proteins. Vacuolation is one of the structural indicators of energy deficit and permeability disorder of membranes in the endometria from treated animals.

The presence of abundant ribosomes and a rough endoplasmic reticulum indicated that the machineries for protein synthesis and transport were present but probably dysfunctional in endometria from the treated animals. Marked shrinkage in mitochondrial size and electron density also indicated some changes in the lipoprotein complex of the membrane, resulting in the formation of myelin bodies. This could have caused impaired endometrial growth in the treated animals.

Our data also suggest that the histomorphological measurements by quantitative morphometry are useful tools for the evaluation of steroidal effects on endometrial stroma and glandular epithelium, as suggested previously [20, 21]. Progesterone-induced secretory activity was profoundly reduced in the endometria from onapristone-treated groups. This is in agreement with the reports of Gemzell-Danielsson et al. [22] and Dockery et al. [23].

Formation of new blood vessels (angiogenesis) in a menstrual cycle-dependent pattern is a distinct process during endometrial development [24, 25]. Progesterone is known to exert mitogenic effects on spiral arteries in endometrium. Decline in the expression of specific angiogenesis and vasopermeability factors (i.e., vascular endometrial growth factor/vascular permeability factor [VEGF/VPF]) has been observed following treatment with mifepristone [26, 27]. In the present study, an intense dilatation of stromal vessels was observed following treatment with onapristone. These results are in agreement with the reports by Reinsch et al. [28] and Slayden et al. [29], where a decrease in blood flow in the endometrium was observed following long-term treatment with antiprogestins. It is likely that the reduced vascular support deprives the endometrium of nutrition and oxygen and causes atrophy. The pronounced atrophy of the endometrium in the animals subjected to long-term onapristone treatment at low doses may also arise because of the derangement in the expressions of progesterone-dependent growth factors such as leukemia inhibitory factor, transforming growth factor [30], keratinocyte growth factor [31], and insulin-like growth factor II [32].

Our data support earlier observations that demonstrated antimitogenic effects of mifepristone administered at 2 mg/day for 30 day [33]. The inhibitory effects of mifepristone on endometrial growth were also observed in humans [34] and monkeys [35]. In the present study an attempt has been made to determine whether the antiprogestin-induced antiestrogenic effects are reflected as change in the concentration or localization of endometrial ER and PR, as both of these receptor proteins are estrogen-dependent. However, we did not find any significant change in the levels of endometrial ER protein in 2.5-mg- and 5.0-mg-treated groups, whereas a decrease in the PR localization was observed following 5.0-mg treatment. This is in contrast to a report demonstrating elevation in endometrial ER and PR after chronic administration of antiprogestin [35]. Our data suggest that the antiestrogenic effect of ZK 98.299 are mediated through a mechanism that does not operate via changes in ER and PR levels. The precise mechanism of antiprogestin action on endometrium still needs to be elucidated. It is likely that the effects of antiprogestins are elicited through some perturbation in postreceptor events. This study also suggests that long-term treatment with antiprogestins does not lead to endometrial hyperplasia.


    ACKNOWLEDGMENTS
 
The authors would like to thank the World Health Organization's Special Programme of Research, Development, and Research Training in Human Reproduction, Geneva, Switzerland, for providing the reagents for the quantification of serum concentrations of estradiol and progesterone. The authors thank Dr. D.D. Manjramkar and Mr. A.S. Patankar for their technical support, and the staff of the Primate Colony for care and husbandry.


    FOOTNOTES
 
1 Correspondence. FAX: 91 22 2413 9412; dirirr{at}vsnl.com Back

Received: 31 May 2002.

First decision: 17 June 2002.

Accepted: 20 December 2002.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brenner RM, Slayden OD. Estrogen action in the endometrium and oviduct of rhesus monkeys during RU486 treatment. In: Beier HM, Spitz IM (eds.), Progesterone Antagonists in Reproductive Medicine and Oncology. Cary, NC: Oxford University Press; 1994:82–97
  2. Brenner RM, Slayden OD. Cyclic changes in the primate oviduct and endometrium. In: Knobil E, Neill JD (eds.), The Physiology of Reproduction. New York: Raven Press; 1994:541–569
  3. Van Look PFA, Ven Hertzen H. Post ovulatory methods of fertility regulation: the emergence of antiprogestogens. In: Van Look PFA, Perez-Polacies G (eds.), Contraceptive Research and Development. New Delhi, India: Oxford University Press; 1994:151–201
  4. Van Look PFA, Van Hertzen H. Antiprogestogens: perspectives from a global research program. In: Donaldson MS (ed.), Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda. Washington: National Academy Press, 1993;253–277
  5. Murphy AA, Castellano PZ. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr Opin Obstet Gynecol 1994 62:269-278
  6. Lamberts SWJ, Tanghe HLJ, Avezaat CJJ, Braakman R, Wijngaarde R, Koper JW, de Jong FH. Mifepristone (RU 486) treatment of meningiomas. J Neuro Neurosurg Psychiatry 1992 55:486-490[Abstract]
  7. Neef G, Beier S, Elger W, Henderson D, Wiechert R. New steroids with antiprogestational and antiglucocorticoid activities. Steroids 1984 44:349-372[CrossRef][Medline]
  8. Puri CP, Van Look PFA. Newly developed competitive progesterone antagonists for fertility control. Front Horm Res 1991 19:127-167
  9. Puri CP, Patil RK, D'souza A, Elger WAG, Pongubala JMR. Pharmacokinetics and pharmacodynamic effects of progesterone antagonist ZK98.299 in female bonnet monkeys. In: Puri CP, Van Look PFA (eds.), Hormone Antagonists for Fertility Regulation. Bombay, India: Indian Society for the Study of Reproduction and Fertility; 1988:123–140
  10. Chwalisz K, Hsiu JG, Williams RF, Hodgen GD. Evaluation of the antiproliferative actions of the progesterone antagonists mifepristone (RU 486) and onapristone (ZK 98.299) on primate endometrium. In: 39th Annual Meeting of the Society for Gynecologic Investigation, San Antonio, Texas, March 18– 21, 1992. Abstract 417.
  11. Ishwad PC, Katkam RR, Hinduja IN, Chwalisz K, Elger W, Puri CP. Treatment with a progesterone antagonist ZK 98.299 delays endometrial development without blocking ovulation in bonnet monkeys. Contraception 1993 48:57-70[CrossRef][Medline]
  12. Croxatto HB, Fuentealba B, Salvatierra AM, Massai R. Clinical strategies for the achievement of endometrial contraception with progesterone antagonists. In: Beier HM, Harper MJK, Chwalisz K (eds.), The Endometrium as a Target for Contraception. Berlin: Springer-Verlag; 1997:259–278
  13. Katkam RR, Gopalkrishnan K, Chwalisz K, Schillinger E, Puri CP. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception. Am J Obstet Gynaecol 1995 173:779-787[CrossRef][Medline]
  14. Sufi SB, Donaldson A, Jeffcoate SL. WHO Matched Reagent Programme Method Manual, 18th ed. Geneva: World Health Organization; 1994
  15. David GX, Herbert J, Wright GDS. The ultrastructure of pineal ganglion in the ferret. J Anat 1973 115:52-79
  16. Reynolds ES. The use of lead citrate at high pH as an electron opaque stain in electron microscopy. J Cell Biol 1963 5:537-543
  17. Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Steirteghem AC. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 1990 5:537-543[Abstract/Free Full Text]
  18. Lessey BA, Danjanovich L, Coutifaris C, Castelbaum A, Albelda SM, Buck CA. Integrin adhesion molecules in the human endometrium correlation with the normal and abnormal menstrual cycle. J Clin Invest 1992 90:188-195
  19. Kitamura Y. Heterogenity of mast cells and phenotypic change between subpopulations. Ann Rev Immunol 1989; 7:59–76.
  20. Ghosh D, De P, Sengupta J. Effects of RU 486 on the endometrial response to deciduogenic stimulus in ovariectomized rhesus monkeys treated with estrogen and progesterone. Hum Reprod 1992 7:1048-1060[Abstract/Free Full Text]
  21. Rogers AW, Hosie MJ, Ortis A, Susil B, Lecton J, Murphy CR. Uterine glandular area during the menstrual cycle and the effects of different in-vitro fertilization related hormonal treatment. Hum Reprod 1996 11:376-379
  22. Gemzell-Danielsson K, Swahn ML, Westland P, Johanisson E, Seppala M, Bygdeman M. Effect of low daily doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1997 12:124-131
  23. Dockery P, Ismail RMJ, Li TC, Warren MA, Cooke ID. The effect of a single dose of mifepristone (RU 486) on the fine structure of the human endometrium during the early luteal phase. Hum Reprod 1997 12:1778-1784[Abstract/Free Full Text]
  24. Findlay JK. Angiogenesis in reproductive tissues. J Endocrinol 1986 111:357-366[Abstract]
  25. Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception 1989 39:103-117[CrossRef][Medline]
  26. Torry DS, Holt VJ, Keenam JA. Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 1996 66:72-80[Medline]
  27. Shifren JL, Iseng JF, Zaloudel CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB, Taylor RN. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996 81:3112-3118[Abstract]
  28. Reinsch RC, Murphy AA, Morales AJ, Samuel SC, Yen MD. The effects of RU486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol 1994 170:1623-1628[Medline]
  29. Slayden OD, Zelinski-Wooten MB, Chwalisz K, Stouffer RL, Brenner RM. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137.316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998 13:269-277
  30. Sachdeva G, Patil V, Katkam RR, Manjramkar DD, Kholkute SD, Puri CP. Expression profiles of endometrial leukemia inhibitory factor, transforming growth factor ß2 and transforming growth factor ß2 receptor in infertile bonnet monkeys. Biol Reprod 2001 65:1-8[Abstract/Free Full Text]
  31. Koji T, Chedid M, Rubin JS, Slayden OD, Csaky KG, Aaronson SA, Brenner RM. Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. J Cell Biol 1994 125:393-401[Abstract/Free Full Text]
  32. Guidice LC, Dsupin BA, Jin IH, Vu TH, Hoffman AR. Differential expression of messenger ribonucleic acids encoding insulin-like growth factors and their receptors in human uterine endometrium and decidua. J Clin Endocrinol Metab 1993 76:1115-1122[Abstract]
  33. Murphy AA, Kettel LM, Morales AJ, Roberts V, Parmky T, Yen SSC. Endometrial effects of long term low dose administration of RU 486. Fertil Steril 1995 63:761-766[Medline]
  34. Kettel LM, Murphy AA, Morales AJ, Ulman A, Baulieu EE, Yen SSC. Treatment of endometriosis with antiprogesterone mifepristone (RU 486). Fertil Steril 1996 65:23-28[Medline]
  35. Neulen J, Williams RF, Hodgen GD. RU 486 induction of dose dependent elevations of estradiol receptors in endometrium from ovariectomized monkeys. J Clin Endocrinol Metab 1990 71:1074-1075[Abstract]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
68/6/1959    most recent
biolreprod.102.007963v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gopalkrishnan, K.
Right arrow Articles by Puri, C.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gopalkrishnan, K.
Right arrow Articles by Puri, C.P.
Agricola
Right arrow Articles by Gopalkrishnan, K.
Right arrow Articles by Puri, C.P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS